Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2019 4
2020 1
2021 4
2022 8
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjects.
Liu G, Xu Z, Yang W, Xue J, Wang Y, Liu Z, Cui Y, Qu X, Chang T, Yu S, Cheng Y, Zhou Y, Chen J, Ren Q, Wang W, Deng Q, Wang Z, Yang H. Liu G, et al. Expert Opin Biol Ther. 2022 Feb;22(2):187-195. doi: 10.1080/14712598.2021.1988567. Epub 2021 Oct 18. Expert Opin Biol Ther. 2022. PMID: 34607519 Clinical Trial.
This study compared the bioequivalence, immunogenicity, and safety of pertuzumab injection (a biosimilar of Perjeta produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd) and Perjeta (produced by Roche Pharma AG) in healthy Chinese males. ...
This study compared the bioequivalence, immunogenicity, and safety of pertuzumab injection (a biosimilar of Perjeta produced by Chia Tai …
Pharmacokinetics and bioequivalence of two pomalidomide capsules in healthy chinese subjects under fasting and fed conditions.
Liu Z, Xu Z, Gao Z, Ren Q, Chang T, Xue J, Yang H. Liu Z, et al. Invest New Drugs. 2023 Feb;41(1):60-69. doi: 10.1007/s10637-022-01320-9. Epub 2022 Nov 28. Invest New Drugs. 2023. PMID: 36441437
The aim of this study was to evaluate the bioequivalence and safety of the generic drug pomalidomide (Chia Tai Tianqing Pharmaceutical Group Co., Ltd) and its originator product Imnovid (Celgene Europe Ltd) in the fasting and fed states, respectively. ...
The aim of this study was to evaluate the bioequivalence and safety of the generic drug pomalidomide (Chia Tai Tianqing Pharmaceutica …
A randomized, double-blind, single-dose, two-way, parallel phase I clinical study comparing the pharmacokinetics and safety of adalimumab injecta and Humira® in healthy Chinese male volunteers.
Wang Y, Gao Z, Liu Z, Liu G, Qu X, Chen J, Ren X, Xu Z, Yang H. Wang Y, et al. Expert Opin Biol Ther. 2022 Feb;22(2):225-234. doi: 10.1080/14712598.2021.1944097. Epub 2021 Jun 30. Expert Opin Biol Ther. 2022. PMID: 34134579 Clinical Trial.
This study compared the bioequivalence, immunogenicity and safety of adalimumab injecta (a biosimilar of Humira produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd) and Humira in healthy Chinese male subjects in a phase I clinical study. ...
This study compared the bioequivalence, immunogenicity and safety of adalimumab injecta (a biosimilar of Humira produced by Chia Tai Tian …
Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor.
Xu Z, Liu Y, Song B, Ren B, Xu X, Lin R, Zhu X, Chen C, Yang S, Zhu Y, Jiang W, Li W, Xia Y, Hu L, Chen S, Chan CC, Li J, Zhang X, Yang L, Tian X, Ding CZ. Xu Z, et al. Bioorg Med Chem Lett. 2024 Apr 24;107:129769. doi: 10.1016/j.bmcl.2024.129769. Online ahead of print. Bioorg Med Chem Lett. 2024. PMID: 38670537
A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects.
Liu Z, Gao Z, Yang W, Zhang L, Xiao N, Qu D, Su Z, Xu K, Liu G, Wang Y, Ren Q, Yu S, Cheng Y, Zhou Y, Deng Q, Zhao Y, Wang Z, Yang H. Liu Z, et al. Expert Opin Drug Metab Toxicol. 2022 Jul-Aug;18(7-8):519-527. doi: 10.1080/17425255.2022.2113382. Epub 2022 Aug 18. Expert Opin Drug Metab Toxicol. 2022. PMID: 35961948 Clinical Trial.
A phase I clinical trial was conducted to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar (Chia Tai Tianqing Pharmaceutical Group Co., Ltd.) and Bevacizumab (Roche Diagnostics GmbH) in healthy Chinese males. ...
A phase I clinical trial was conducted to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar (Chia Tai Tian …
A randomized, crossover, phase I clinical study to evaluate bioequivalence and safety of tofacitinib and Xeljanz® in Chinese healthy subjects.
Xu Z, Wang Y, Liu Z, Zhang R, Zhou Y, Yu J, Lan J, Liang W, Liu G, Qu X, Chen J, Su Z, Yu S, Cheng Y, Wang W, Ren Q, Deng Q, Zhao Y, Yang H. Xu Z, et al. Int Immunopharmacol. 2022 Aug;109:108780. doi: 10.1016/j.intimp.2022.108780. Epub 2022 Apr 20. Int Immunopharmacol. 2022. PMID: 35461158 Clinical Trial.
A phase I clinical trial was conducted to compare the bioequivalence and safety of tofacitinib (Chia Tai Tianqing Pharmaceutical Group Co., Ltd.) and Xeljanz (Pfizer Inc.) in healthy Chinese subjects, providing basis for the clinical application of tofacitinib. ...
A phase I clinical trial was conducted to compare the bioequivalence and safety of tofacitinib (Chia Tai Tianqing Pharmaceutical Grou …
A randomized, open-label, single-dose, two-cycle crossover study to evaluate the bioequivalence and safety of lenvatinib and Lenvima® in Chinese healthy subjects.
Xu Z, Wang Y, Liu G, Chen J, Wang W, Cheng Y, Ren Q, Cui Y, Yang W, Liu Z, Chen X, Xue J, Chang T, Qu X, Yu S, Zhou Y, Xu K, Su Z, Deng Q, Zhao Y, Yang H. Xu Z, et al. Expert Opin Investig Drugs. 2022 Jul;31(7):737-746. doi: 10.1080/13543784.2022.2067528. Epub 2022 Apr 19. Expert Opin Investig Drugs. 2022. PMID: 35427205 Clinical Trial.
17 results